IL153733A0 - A new use for deferiprone - Google Patents

A new use for deferiprone

Info

Publication number
IL153733A0
IL153733A0 IL15373301A IL15373301A IL153733A0 IL 153733 A0 IL153733 A0 IL 153733A0 IL 15373301 A IL15373301 A IL 15373301A IL 15373301 A IL15373301 A IL 15373301A IL 153733 A0 IL153733 A0 IL 153733A0
Authority
IL
Israel
Prior art keywords
deferiprone
patient
new use
cardiac disease
induced cardiac
Prior art date
Application number
IL15373301A
Other languages
English (en)
Original Assignee
Apotex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4166629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL153733(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apotex Inc filed Critical Apotex Inc
Publication of IL153733A0 publication Critical patent/IL153733A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15373301A 2000-06-30 2001-06-28 A new use for deferiprone IL153733A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2313270A CA2313270C (en) 2000-06-30 2000-06-30 Use of deferiprone in treating and preventing iron-induced cardiac disease
PCT/CA2001/000956 WO2002002114A1 (en) 2000-06-30 2001-06-28 A new use for deferiprone

Publications (1)

Publication Number Publication Date
IL153733A0 true IL153733A0 (en) 2003-07-06

Family

ID=4166629

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15373301A IL153733A0 (en) 2000-06-30 2001-06-28 A new use for deferiprone
IL153733A IL153733A (en) 2000-06-30 2002-12-29 Use of deferiprone for the preparation of iron chelating agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL153733A IL153733A (en) 2000-06-30 2002-12-29 Use of deferiprone for the preparation of iron chelating agents

Country Status (16)

Country Link
US (2) US7049328B2 (de)
EP (1) EP1294379B1 (de)
CN (3) CN101380322B (de)
AT (1) ATE427107T1 (de)
AU (2) AU7040201A (de)
BR (1) BR0112280A (de)
CA (1) CA2313270C (de)
CY (1) CY1109191T1 (de)
DE (1) DE60138189D1 (de)
DK (1) DK1294379T3 (de)
ES (1) ES2324978T3 (de)
HK (1) HK1043316A1 (de)
IL (2) IL153733A0 (de)
PT (1) PT1294379E (de)
WO (1) WO2002002114A1 (de)
ZA (1) ZA200109322B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095728A1 (en) * 2006-02-22 2007-08-30 Arnold Munnich The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
CN101679263B (zh) 2007-03-28 2014-01-15 阿普泰克斯科技公司 去铁酮的氟化衍生物
EP2268282B1 (de) * 2008-04-25 2014-10-29 Apotex Technologies Inc. Flüssige formulierung von deferipron mit angenehmem geschmack
GEP20146008B (en) 2009-07-03 2014-01-10 Apotex Tech Inc Fluorinated derivatives of 3-hydroxypyridin-4-ones
US8603814B2 (en) * 2009-07-20 2013-12-10 Rutgers The State University Of New Jersey Method of inhibiting nonsense-mediated mRNA decay
US9849146B2 (en) 2009-07-20 2017-12-26 Rutgers, The State University Of New Jersey Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
AU2012327224A1 (en) * 2011-11-18 2013-06-06 Apotex Technologies Inc. Methods of treatment with deferiprone
WO2016029158A2 (en) * 2014-08-21 2016-02-25 Collaborative Medicinal Development Llc Compositions and methods for extending lifespan
KR20230004944A (ko) * 2016-08-05 2023-01-06 아브페로 파마슈티칼스, 인크. 금속-매개 상태를 치료하기 위한 투여 요법
CN106983746A (zh) * 2017-03-23 2017-07-28 武汉联合药业有限责任公司 一种药物组合物及其用途
MD3684344T2 (ro) 2017-10-25 2025-09-30 Chiesi Farm Spa Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora
EP3999059A1 (de) * 2019-07-19 2022-05-25 Vifor (International) Ag Ferroportin-inhibitoren zur verwendung in der behandlung von transfusionsabhängiger beta-thalassämie (tdt)
CN114217071B (zh) * 2021-12-01 2023-11-14 柏荣诊断产品（上海）有限公司 一种高特异性透散射一体法铁蛋白胶乳比浊检测试剂盒
AU2023253115A1 (en) 2022-04-11 2024-11-21 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
CN115429881A (zh) * 2022-09-02 2022-12-06 中国医学科学院基础医学研究所 铁螯合剂治疗β-连环蛋白活化突变的肿瘤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2118176B (en) * 1982-03-24 1985-12-04 Nat Res Dev Pharmaceutical compositions
US5922761A (en) * 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor

Also Published As

Publication number Publication date
ES2324978T3 (es) 2009-08-21
ATE427107T1 (de) 2009-04-15
CN101933924A (zh) 2011-01-05
CY1109191T1 (el) 2014-07-02
CN101380322B (zh) 2015-06-24
DE60138189D1 (de) 2009-05-14
CN1331971A (zh) 2002-01-23
EP1294379A1 (de) 2003-03-26
WO2002002114A1 (en) 2002-01-10
US20060122273A1 (en) 2006-06-08
ZA200109322B (en) 2002-10-21
AU7040201A (en) 2002-01-14
US7049328B2 (en) 2006-05-23
CA2313270C (en) 2011-09-13
IL153733A (en) 2010-04-29
DK1294379T3 (da) 2009-06-02
EP1294379B1 (de) 2009-04-01
HK1130422A1 (en) 2009-12-31
CN101380322A (zh) 2009-03-11
PT1294379E (pt) 2009-05-04
US20030158234A1 (en) 2003-08-21
CA2313270A1 (en) 2001-12-30
AU2001270402B9 (en) 2006-03-02
BR0112280A (pt) 2003-05-13
HK1043316A1 (zh) 2002-09-13
AU2001270402B2 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
GB0225474D0 (en) Therapeutic agents
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
GB0223038D0 (en) Therapeutic compounds
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
AU2459402A (en) Composition
WO2002053101A3 (en) Method for treating fibrotic diseases or other indications
MY119375A (en) Treatment of tinnitus using neuroprotective agents
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
TWI367751B (en) Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
BG106118A (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
NZ592615A (en) Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
EP1485096A4 (de) Verfahren zur verhütung oder behandlung von herzarrhythmie
GB0130677D0 (en) Medicaments and novel compounds
NZ592613A (en) Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
SE9902597D0 (sv) New use
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
MXPA03003980A (es) Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.
AU4258601A (en) Divided dose therapies with vascular damaging activity
IL146962A0 (en) Aminotetralin derivatives for the therapy of cardiovascular diseases
EP1270000A3 (de) Benzoesäure-substituierte Benzopyrane zur Behandlung von Atherosklerose
SI1553938T1 (sl) Uporaba epotilonskih derivatov za zdravljenje hiperparatiroidizma
JP2002533400A5 (de)
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture